Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Trial details
- Registry ID
- NCT03108495
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as TIL, autologous tumor infiltrating lymphocytes; pembrolizumab (anti-PD-1 immunotherapy)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495 | IOVA | Phase 2 | Terminated | 2025-08-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |